Lunit Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Beomseok Brandon Suh

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	pas de données

Mises à jour récentes de la gestion

Recent updates

Subdued Growth No Barrier To Lunit Inc. (KOSDAQ:328130) With Shares Advancing 60%

Nov 20

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Apr 19

PDG

Beomseok Brandon Suh

no data

Titularisation

Mr. Beomseok Brandon Suh is Chief Executive Officer of Lunit Inc. He studied medicine in Seoul National University College of Medicine and is a board certified physician in Family Medicine, trained at Seou...

Lunit Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Recent updates

Subdued Growth No Barrier To Lunit Inc. (KOSDAQ:328130) With Shares Advancing 60%

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Price target decreased by 42% to ₩58,000

Lunit's Ai for Tuberculosis Detection Tops in 12-Product Comparative Study

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit Announces the Appointment of Teri Thomas as Chief Business Officer of Its Cancer Screening Group

Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Lunit Inc. announced that it expects to receive KRW 171.5 billion in funding from a group of investors

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Lunit Announces Publication of New Study Featuring Lunit SCOPE IO

Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million.

New minor risk - Shareholder dilution

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology

Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America

Third quarter 2023 earnings released: ₩948 loss per share (vs ₩1,576 loss in 3Q 2022)

Lunit Inc. Receives U.S. Food and Drug Administration (FDA) 510(K) Clearance for its 3D Breast Tomosynthesis (DBT) Ai Solution, Lunit Insight DBT

Lunit Inc. has completed a Follow-on Equity Offering in the amount of KRW 200.20077 billion.

Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes

New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023

Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Lunit Inc. Provides Revenue Guidance for the Second Half of the Year 2022

PDG

Titularisation